Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform treatment of cancer and autoimmune and inflammatory diseases by developing allogeneic, iPSC-derived NK and T cell therapies.
PRESS RELEASES + EVENTS
view all
19-March-2024
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company…
14-March-2024
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
– Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas…
About us
We are building an industry leading allogeneic iPSC-derived cell therapy platform for cancer and autoimmune and inflammatory diseases.
OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.